Mirabegron is a β 3-adrenoceptor agonist developed for the treatment of OAB, with a mechanism of action distinct from that of antimuscarinics. In a randomized, double-blind, placebo- and active ...

Myrbetriq (mirabegron) – sold as Betanis and Betmiga in some markets – is an extended-release selective β3-adrenoceptor agonist therapy used to treat overactive bladder with symptoms of ...

MILAN, Italy — The safety and adverse-effect profile of mirabegron (Myrbetriq, Astellas Pharma) for overactive bladder compares favorably with placebo and tolterodine, new research shows.

The ruling blocks Lupin and Zydus Life from selling their generic version of Mirabegron, the bioequivalent of Astellas' overactive bladder drug, Myrbetriq, in the United States. According to the ...

Zydus Lifesciences US subsidiary Zydus Pharmaceuticals USA Inc has received final approval from the United States Food and Drug Administration USFDA to market Mirabegron Extended-Release Tablets ...